These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21143162)

  • 1. Pulmonary hypertension: role of combination therapy.
    Meis T; Behr J
    Curr Vasc Pharmacol; 2011 Jul; 9(4):457-64. PubMed ID: 21143162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for the treatment of pulmonary arterial hypertension.
    Levinson AT; Klinger JR
    Ther Adv Respir Dis; 2011 Dec; 5(6):419-30. PubMed ID: 21849335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension.
    O'Callaghan DS; Savale L; Jaïs X; Natali D; Montani D; Humbert M; Simonneau G; Sitbon O
    Respir Med; 2010 Jul; 104 Suppl 1():S74-80. PubMed ID: 20418081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.
    Bajwa AA; Qureshi T; Shujaat A; Seeram V; Jones LM; Al-Saffar F; Cury JD
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):395-400. PubMed ID: 25613465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in the management of pulmonary arterial hypertension.
    Buckley MS; Staib RL; Wicks LM
    Int J Clin Pract Suppl; 2013 May; (179):13-23. PubMed ID: 23578069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension.
    Gokhman R; Smithburger PL; Kane-Gill SL; Seybert AL
    J Cardiovasc Pharmacol; 2010 Dec; 56(6):686-95. PubMed ID: 20838230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC; Howard LS
    Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on medical therapy for pulmonary arterial hypertension.
    Wu Y; O'Callaghan DS; Humbert M
    Curr Hypertens Rep; 2013 Dec; 15(6):614-22. PubMed ID: 24122306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination treatment in pulmonary arterial hypertension].
    Kramer MR
    Harefuah; 2011 Apr; 150(4):383-8, 417. PubMed ID: 22164922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial dual oral combination therapy in pulmonary arterial hypertension.
    Sitbon O; Sattler C; Bertoletti L; Savale L; Cottin V; Jaïs X; De Groote P; Chaouat A; Chabannes C; Bergot E; Bouvaist H; Dauphin C; Bourdin A; Bauer F; Montani D; Humbert M; Simonneau G
    Eur Respir J; 2016 Jun; 47(6):1727-36. PubMed ID: 26989105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M
    Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
    Zhu B; Wang L; Sun L; Cao R
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
    Waxman AB; Zamanian RT
    Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic therapy for pulmonary artery hypertension.
    Nair A
    Curr Opin Cardiol; 2020 Nov; 35(6):643-656. PubMed ID: 32897888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of pulmonary arterial hypertension.
    Ramani GV; Gill S
    Curr Pharm Des; 2013; 19(22):3963-73. PubMed ID: 23228314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.